Ellen Scherl News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Dr. Iliyan D. Iliev, an associate professor of immunology in medicine in the Division of Gastroenterology and Hepatology, co-director of the Microbiome Core and a member of the Jill Roberts Institute for Research in Inflammatory Bowel Disease (IBD) at Weill Cornell Medicine, is the lead investigator on a grant to Weill Cornell Medicine from The Leona M. and Harry B. Helmsley Charitable Trust to target pathogenic fungi in patients with Crohn's disease.

Individual Candida albicans yeast strains in the human gut are as different from each other as the humans who carry them, and some C. albicans strains may

Some Candida albicans yeast strains may damage the gut of patients with inflammatory bowel disease, according to a new study, suggesting a possible way to tailor treatments to individual patients in the future.

Individual Candida albicans yeast strains in the human gut are as different from each other as the humans that carry them, and some C. albicans strains may damage the gut of patients with inflammatory bowel disease (IBD), according to a new study from researchers at Weill Cornell Medicine.

February 11, 2021 The discovery of an “Achilles’ heel” in a type of gut bacteria that causes intestinal inflammation in patients with Crohn’s disease may lead to more targeted therapies for the difficult-to-treat disease, according to researchers at Weill Cornell Medicine and NewYork-Presbyterian. In a study published Feb. 5 in Cell Host and Microbe, the investigators showed that patients with Crohn’s disease have an overabundance of a type of gut bacteria called adherent-invasive Escherichia coli (AIEC), which promotes inflammation in the intestine. Their experiments revealed that...